| 2024-04-25 | -1.75 % |
|
| 2024-04-24 | -0.09 % |
|
| 2024-04-23 | +0.8 % |
|
| 2024-04-22 | +0.37 % |
|
| 2024-04-18 | -0.8 % |
- The article compares Regeneron Pharmaceuticals and Oragenics in terms of earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, and dividends, with Regeneron Pharmaceuticals having a higher target price and being considered more favorable by analysts. Regeneron Pharmaceuticals stock went down by -0.8% possibly due to market fluctuations or profit-taking by investors.
- The article discusses how Cantor Fitzgerald maintained a neutral rating on Regeneron Pharmaceuticals (REGN) stock with a price target of $925.00, and other analysts raised their target prices for the company. The stock of Regeneron Pharmaceuticals went down by 0.8% on the previous day due to a variety of factors including market conditions, analyst ratings, and financial information such as earnings and revenue.
- Regeneron Pharmaceuticals' stock was down -0.8% following a mixed analysis from research firms, maintaining an average "Moderate Buy" rating, with the stock being given differing recommendations from "Sell" to "Strong Buy" and a 1-year target price of $970.57; the recent dip in stock price could possibly be due to various factors such as market conditions, company performance, or insider selling activities.
|
| 2024-04-17 | +0.79 % |
|
| 2024-04-15 | -0.68 % |
|
| 2024-04-11 | -1.7 % |
|
| 2024-04-10 | -0.81 % |
|
| 2024-04-08 | -0.45 % |
|
| 2024-04-05 | +0.61 % |
|
| 2024-04-01 | +0.71 % |
|
| 2024-03-28 | -0.39 % |
- The article discusses Truist Financial reaffirming a buy rating on Regeneron Pharmaceuticals (REGN) with a $1,135.00 price objective, along with other analysts issuing various ratings on the stock, which has an average price target of $967.59. REGN stock opened at $966.30, has a market capitalization of $106.06 billion, and last posted its quarterly earnings report on Feb 2nd. The stock recently went down by -0.39%, possibly due to insiders selling company shares and reduced stake by institutional investors and hedge funds.
- The article discusses how Schechter Investment Advisors LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (REGN) by 1.3% in the fourth quarter, along with other hedge funds also adjusting their stakes in the stock, leading to a 0.39% decrease in REGN stock. This decrease could be due to potential concerns from investors related to insider selling and adjustments in institutional holdings, along with market factors influencing the stock price movement.
- The article reports that despite a positive outlook from research analysts at Truist Financial with a $1,135.00 price target for Regeneron Pharmaceuticals (REGN) stock, it experienced a 0.39% decline last night; potential reasons for the stock's decrease could include market fluctuations, investor sentiment, or profit-taking behaviors.
|
| 2024-03-27 | +0.29 % |
|
| 2024-03-26 | +0.26 % |
|
| 2024-03-25 | -0.64 % |
|
| 2024-03-22 | -0.08 % |
- The article summarizes that Regeneron Pharmaceuticals, Inc. (REGN) stock received a "Moderate Buy" rating from analysts, with a one-year price target of $959.09, and several analysts issuing positive recommendations on the stock; however, the stock went down by -0.08%. The stock might have experienced a decline due to general market fluctuations, profit-taking behaviors, or concerns related to insider selling activities as senior executives and insiders sold a significant amount of shares in recent months. Additionally, macroeconomic factors or industry-specific news could have contributed to the stock's decline.
- Summary: The article discusses the termination by Intellia Therapeutics of its Factor IX Co-Development and Co-Funding Agreement with Regeneron Pharmaceuticals, resulting in Regeneron no longer being obligated to share development costs or profits for gene editing products directed to factor IX, thus leading to a small decrease in Regeneron Pharmaceuticals' stock value.
Reason for Regeneron Pharmaceuticals stock going down: The stock went down due to the termination of the Co-Development and Co-Funding Agreement between Intellia Therapeutics and Regeneron Pharmaceuticals, relieving Regeneron of certain financial obligations related to gene editing products directed to factor IX.
- The article discusses how Intellia Therapeutics notified Regeneron Pharmaceuticals about opting out of their co-development and co-funding agreement, leading to Regeneron's stock decline, as Intellia will no longer share development costs or profits related to gene-editing products, impacting Regeneron's financial outlook.
|
| 2024-03-20 | +0.34 % |
- The article discusses Alvotech's recent financial results and pipeline updates, which include positive clinical study results and product launches, possibly contributing to the increase in Regeneron Pharmaceuticals (REGN) stock.
- The article provides a summary of Alvotech's financial results and recent pipeline and corporate highlights, with the CEO mentioning significant achievements including FDA approvals and successful clinical development milestones, leading to 0.34% increase in Regeneron Pharmaceuticals (REGN) stock due to the positive developments and expectations for further market launches and growth.
- The article provides an update on Alvotech, a global biotech company, including recent pipeline and corporate highlights, financial results for full year 2023, and an overview of various biosimilar products sales and development. Regeneron Pharmaceuticals' stock may have gone up due to positive news regarding Alvotech's approvals and advancements in developing biosimilar medicines such as AVT02, AVT04, AVT05, AVT06, and AVT03, which could have impacted investor sentiment positively.
|
| 2024-03-18 | -0.47 % |
|
| 2024-03-13 | -0.53 % |
|
| 2024-03-12 | +0.64 % |
- The article discusses how Scotia Capital Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (REGN) during the third quarter, and various hedge funds and analysts have been buying and selling shares of REGN, thus contributing to the stock's 0.64% increase. The stock has been performing well, with several hedge funds and analysts showing confidence in the company, contributing to its positive trajectory.
- The article discusses Penserra Capital Management LLC's reduction in their position in Regeneron Pharmaceuticals, Inc. (REGN) and mentions other hedge funds and institutional investors modifying their holdings, leading to a slight increase of 0.64% in REGN stock price; this rise is likely attributed to positive quarterly earnings results, revenue exceeding analyst expectations, and receiving favorable ratings from various analysts.
- The article discusses the recent increase of 0.64% in Regeneron Pharmaceuticals (REGN) stock and highlights that Sei Investments Co. reduced its holdings of Regeneron Pharmaceuticals shares by 3.9% during the third quarter, along with other institutional investors making modifications to their holdings of REGN. The stock went up due to factors like management maneuvers, stock transactions by executives, and positive quarterly earnings results, leading to increased target prices and ratings by equity analysts.
|
| 2024-03-11 | -0.45 % |
|
| 2024-03-08 | -0.46 % |
- The article discusses the current trends in the biotech industry, including a significant rally due to recent developments and optimism about interest rate reductions. While the S&P Biotechnology Select Industry Index is up year to date, Regeneron Pharmaceuticals (REGN) stock went down by -0.46% last night due to various factors affecting the sector, such as resurgence of therapies targeting obesity, M&A activities, and expectations for FDA approvals and an enhanced IPO market in 2024.
- The article discusses how Regeneron Pharmaceuticals' EYLEA HD showed positive results in treating wet age-related macular degeneration and diabetic macular edema, with extended dosing regimens being non-inferior to standard treatments, leading to an approval in multiple countries. The stock of Regeneron Pharmaceuticals likely went down due to factors unrelated to the positive results of their drug trials, such as broader market trends, industry news, or investor sentiment.
|
| 2024-03-04 | -1.18 % |
|
| 2024-03-01 | +1.73 % |
|
| 2024-02-29 | -2.18 % |
- Regeneron Pharmaceuticals (REGN) stock was down -2.18% last night. The reason for this decline is not mentioned in the provided article, as the article predominantly discusses Elanco Animal Health Incorporated's response to Ancora Holdings Group, LLC.
- The article discusses how institutional investors have modified their holdings in Regeneron Pharmaceuticals (REGN), with Connor Clark & Lunn Investment Management Ltd. reducing its holdings by 84.3%, leading to the stock being down by -2.18% last night. This decrease in stock value may be attributed to the sell-offs by these investors, like Connor Clark & Lunn Investment Management Ltd., and other related institutional changes mentioned in the article.
- Summary: Regeneron Pharmaceuticals' stock (REGN) dropped by -2.18% as EVP Joseph J. Larosa sold 1,000 shares of the company's stock, causing a decline in value following the transaction.
Reason for stock decline: The stock price of Regeneron Pharmaceuticals (REGN) went down after an executive vice president sold 1,000 shares of the company's stock, which could have led to investor concerns and a decrease in stock value.
|
| 2024-02-28 | -0.58 % |
|
| 2024-02-27 | +0.41 % |
|
| 2024-02-26 | +0.82 % |
|
| 2024-02-23 | +1.69 % |
|
| 2024-02-21 | +0.63 % |
|
| 2024-02-16 | -0.7 % |
|
| 2024-02-13 | -0.69 % |
|
| 2024-02-07 | +0.07 % |
|
| 2024-02-06 | +0.16 % |
|
| 2024-02-05 | -0.94 % |
|
| 2024-02-02 | -1.32 % |
|
| 2024-02-01 | +1.59 % |
|
| 2024-01-31 | -1.77 % |
|
| 2024-01-30 | +0.41 % |
|
| 2024-01-29 | +1.68 % |
|
| 2024-01-26 | -0.93 % |
|
| 2024-01-25 | +0.07 % |
|
| 2024-01-24 | -0.66 % |
|
| 2024-01-22 | +1.01 % |
|
| 2024-01-19 | +0.37 % |
|
| 2024-01-08 | -1.13 % |
|
| 2024-01-05 | +0.11 % |
|
| 2024-01-04 | -0.59 % |
|
| 2024-01-03 | +1.39 % |
|
| 2023-12-18 | -0.96 % |
|
| 2023-12-11 | +0.99 % |
|
| 2023-12-07 | +1.61 % |
|
| 2023-12-06 | +1.81 % |
|
| 2023-12-05 | -0.29 % |
|
| 2023-11-27 | -0.03 % |
- In a positive development for Regeneron Pharmaceuticals (REGN), their drug Dupixent showed significant improvement in symptoms for patients with a chronic lung disease, however, the stock went down by -0.03% last night and the reason for the decline is not mentioned in the article.
- Regeneron Pharmaceuticals' stock went down by 0.03% after the company announced positive results from its Phase 3 trial of Dupixent in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) and plans to submit the data to the FDA by the end of the year.
- The article discusses the performance of Alnylam Pharmaceuticals, a biotechnology company specializing in RNA interference therapeutics for rare diseases. It highlights the company's financial resilience, with net product revenues for the third quarter of 2023 slightly below estimates but still robust. The article mentions Alnylam's competition with other biopharmaceutical companies, including Regeneron Pharmaceuticals. It also discusses regulatory events and upcoming trial results that could impact the company's stock performance. The article encourages readers to explore further insights and tips from InvestingPro, a subscription service offering comprehensive analysis. The stock performance of Alnylam Pharmaceuticals has been under scrutiny, particularly after the FDA issued a Complete Response Letter for one of its drugs. However, the company's revenue growth and positive sentiment from analysts suggest a promising future. The article concludes by promoting InvestingPro's discounted subscription offering for readers interested in exploring Alnylam's prospects further.
- Regeneron Pharmaceuticals (REGN) stock went down by -0.03% due to the announcement that Formycon AG submitted a marketing authorization application for FYB203, a biosimilar candidate for Eylea (Aflibercept), which is a competitor to Regeneron's drug.
|
| 2023-11-14 | -0.38 % |
|
| 2023-11-10 | -0.16 % |
|
| 2023-11-09 | -2.74 % |
|
| 2023-11-07 | -0.19 % |
|
| 2023-11-03 | -0.23 % |
|
| 2023-11-02 | +3.48 % |
- Regeneron Pharmaceuticals (REGN) reported a decrease in third-quarter profits compared to the previous year, but still exceeded expectations, and its stock went up by 3.48%. The company's revenue increased by 14.5%, despite the profit decline, indicating the company's financial strength. Additionally, Regeneron has a strong return on assets, aggressive share buyback strategy, and the ability to cover interest payments with cash flows. Investors remain confident in Regeneron's potential, as indicated by its high stock price and market cap.
- Regeneron Pharmaceuticals stock (REGN) went up by 3.48% as the company beat Wall Street estimates in its third-quarter profit, due to strong demand for its eczema treatment Dupixent. Increased sales of Dupixent offset a decline in sales of its eye drug Eylea, which faced competition from Roche's Vabysmo.
- Regeneron Pharmaceuticals (REGN) stock went up by 3.48% last night, likely due to the company's strong financial results for the third quarter of 2023, driven by revenue growth and successful product performance, including the launch of EYLEA HD and the progress of their pipeline.
- Regeneron Pharmaceuticals (REGN) stock increased by 3.48% yesterday, and the reason for the increase is not mentioned in the article.
- Regeneron Pharmaceuticals (REGN) stock went up by 3.48% due to the company's strong financial results in the third quarter of 2023 and positive business updates, including double-digit revenue growth driven by performance in Dupixent and Libtayo, as well as strong uptake of EYLEA HD following its recent launch.
- The stock of Regeneron Pharmaceuticals went up by 3.48% due to the company's strong third-quarter performance, driven by the successful launch of its high-dose Eylea drug.
|
